A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and bipartisan health care challenges. The blog highlights how the 340B program helps keep drug prices lower than they otherwise would be for all stakeholders; helps lower national expenditures on health care services; and helps protect the safety net for Americans.

“The 340B program was created over 30 years ago with strong bipartisan congressional support and it ought to be preserved in the same manner,” the blog states. “We urge Congress to not allow the self-interested needs of the pharmaceutical industry to supplant the needs of patients and communities across this country who rely on the 340B program for access to affordable, high-quality health care every day.”

Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…